ZMAX Drug Patent Profile

When do Zmax patents expire, and when can generic versions of Zmax launch?

Zmax is a drug marketed by Pf Prism Cv and is included in one NDA.

The generic ingredient in ZMAX is azithromycin. There are thirty-two drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the azithromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zmax

A generic version of ZMAX was approved as azithromycin by PLIVA on November 14^th, 2005.

Summary for ZMAX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	67
Drug Prices:	Drug price information for ZMAX
What excipients (inactive ingredients) are in ZMAX?	ZMAX excipients list
DailyMed Link:	ZMAX at DailyMed

See drug prices for ZMAX

US Patents and Regulatory Information for ZMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005		DISCN	Yes	No

Expired US Patents for ZMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	6,068,859
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	6,268,489
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	7,887,844
Pf Prism Cv	ZMAX	azithromycin	FOR SUSPENSION, EXTENDED RELEASE;ORAL	050797-001	Jun 10, 2005	6,984,403

International Patents for ZMAX

See the table below for patents covering ZMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	964678
Algeria	1880	Forme posologique d'azithromycine et son procédé de production.
Hungary	211862
Tunisia	SN95051	PROCEDE DE PRODUCTION D'UNE FORME PHARMACEUTIQUE D'AZITHROMYCINE
Panama	8611501	FORMAS DE DOSIFICACION DE AZITROMICINA CON EFECTOS SECUNDARIOS REDUCIDOS

Market Dynamics and Financial Trajectory for ZMAX

Last updated: February 20, 2026

What is ZMAX and Its Current Market Position?

ZMAX (azitromycin extended-release suspension) is a macrolide antibiotic approved by the FDA in 2005. It is marketed primarily for uncomplicated respiratory tract infections, including acute bacterial sinusitis, bronchitis, and community-acquired pneumonia. As a branded drug, it competes within the respiratory antibiotic segment, a market characterized by established generics and rising resistance concerns.

The drug is marketed by Pfizer in the United States and globally by other partners. Its sale peaked during the late 2000s, but its market share has experienced declines due to generics and the emergence of alternative antibiotics. As of 2022, ZMAX generates annual revenue in the low hundreds of millions USD.

How Has the Market Evolved for ZMAX?

Market Share and Competitive Landscape

• The antibiotic market is mature, with significant generic penetration. As of 2022, generics of azithromycin account for over 90% of sales in the class.
• ZMAX's formulation provides an extended-release profile, allowing for single-dose therapy, which provides a convenience advantage, but did not significantly alter market share dynamics.
• Resistance development against macrolides has limited their long-term efficacy, prompting shifts toward newer agents such as doxycycline and fluoroquinolones.

Key Collaborations and Distribution Channels

• Pfizer maintains direct sales and partnerships with hospitals and retail chains.
• The drug’s distribution is influenced by reimbursement policies, formulary inclusion, and prescriber preferences.
• Pharmacy benefit managers (PBMs) and insurance formularies impact the drug’s penetration, with generic azithromycin generally favored due to lower cost.

Regulatory and Policy Impact

• The CDC emphasizes antimicrobial stewardship, which could restrict broad antibiotic use.
• Recent updates in guidelines recommend narrower-spectrum agents where appropriate, reducing overall azithromycin use.
• Newer formulations and combination therapies are being developed to combat resistance, challenging ZMAX’s market share.

What is the Financial Trajectory of ZMAX?

Revenue Trends

Year	Estimated Revenue (USD millions)	Notes
2018	250	Stable sales within U.S. market
2019	230	Slight decline due to generics resurgence
2020	210	Impact from COVID-19 reducing outpatient prescriptions
2021	200	Continued decline, competitive pressures
2022	180	Approximate, reflecting generic dominance

Revenue Drivers and Inhibitors

• Drivers: Single-dose convenience, brand loyalty among prescribers, hospital formulary inclusion.
• Inhibitors: Price competition from generics, antimicrobial stewardship policies, resistance emergence, and alternative therapies.

Cost Structure and Profitability Outlook

• The drug’s manufacturing costs are relatively stable due to its single-dose formulation.
• Margins decline as generic azithromycin dominates the market.
• Pfizer's strategic focus has shifted toward innovative and specialty medicines, limiting investment in ZMAX.

Future Market Potential

• Limited growth prospects due to patent expiration vulnerabilities and the market’s shift toward narrow-spectrum antibiotics.
• Emerging resistance and stewardship policies reduce prescription volume.
• Entry of new formulations or combination drugs could threaten or expand ZMAX's niche but remains uncertain.

How Do External Factors Influence ZMAX’s Financial Trajectory?

Resistance Trends and Stewardship Policies

• Resistance: Increasing azithromycin resistance in pathogens causes prescribers to favor alternative agents.
• Policies: Stewardship programs restrict unnecessary antibiotic use, directly reducing ZMAX prescriptions.

Demographic and Epidemiological Trends

• Aging populations could sustain demand in respiratory infections but are counterbalanced by increased resistance.
• The COVID-19 pandemic temporarily reduced outpatient antibiotic prescriptions by disrupting healthcare access.

Competitive Innovation

• Similar extended-release formulations or combination drugs under development may erode ZMAX's market.
• Biosimilar or generic versions of azithromycin limit profit margins for branded ZMAX.

Key Takeaways

• ZMAX faces declining market share amid generic competition, resistance issues, and restrictive policies.
• Revenue has declined approximately 20% annually from 2018 to 2022.
• Future growth is unlikely without formulation innovations, new indications, or combination therapies.
• The drug’s sales are heavily influenced by broader antimicrobial stewardship and resistance trends.
• Pfizer has reduced strategic emphasis on ZMAX, redirecting resources toward innovative therapeutic areas.

Frequently Asked Questions

1. What is the main obstacle to ZMAX’s market growth?
Market growth is limited by the dominance of generic azithromycin, increasing resistance, and policies promoting antimicrobial stewardship.

2. Can ZMAX regain market share?
Regaining market share requires differentiation through new formulations, indications, or combination therapies. Current market conditions favor generics and stewardship-driven restrictions.

3. How does resistance affect ZMAX’s sales?
Rising resistance decreases clinical effectiveness, leading prescribers to choose alternative agents and reducing ZMAX’s utilization.

4. What is the outlook for Pfizer’s investment in ZMAX?
Pfizer’s strategic focus has shifted away from ZMAX, with limited reinvestment anticipated unless significant innovations or new indications emerge.

5. Are there opportunities in the ZMAX segment?
Opportunities depend on overcoming resistance and regulatory challenges. Developing formulations that extend patent protection or target specific resistant strains could provide avenues for growth.

References

1. U.S. Food and Drug Administration. (2005). ZMAX (azithromycin extended-release) approval documents.
2. Centers for Disease Control and Prevention. (2021). Antibiotic resistance threats in the United States.
3. IQVIA. (2022). U.S. prescription drug data.
4. Pfizer. (2022). Annual report and product pipeline.
5. GlobalData. (2022). Antibiotic market analysis and forecasts.